MA33849B1 - Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels - Google Patents

Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels

Info

Publication number
MA33849B1
MA33849B1 MA35005A MA35005A MA33849B1 MA 33849 B1 MA33849 B1 MA 33849B1 MA 35005 A MA35005 A MA 35005A MA 35005 A MA35005 A MA 35005A MA 33849 B1 MA33849 B1 MA 33849B1
Authority
MA
Morocco
Prior art keywords
piperazin
phenylamino
pyrimidin
dimethoxy
dichloro
Prior art date
Application number
MA35005A
Other languages
Arabic (ar)
English (en)
Inventor
Joerg Berghausen
Prasad Koteswara Kapa
Joseph Mckenna
Joel Slade
Raeann Wu
Zhengming Du
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43983750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33849(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33849B1 publication Critical patent/MA33849B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente technologie concerne de nouvelles formes cristallines anhydres et hydratées de 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1-{6-[4-(4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin-4-yl}-1-méthyl-urée, des polymorphes amorphes et cristallines anhydres de son sel d'acide monophosphorique, et le sel chlorhydrate, incluant son dihydrate. La présente technologie concerne également des procédés de préparation de diverses formes, des compositions les contenant et des procédés de traitement les employant.
MA35005A 2009-12-07 2012-06-26 Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels MA33849B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26715509P 2009-12-07 2009-12-07
PCT/US2010/059108 WO2011071821A1 (fr) 2009-12-07 2010-12-06 Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1-{6-[4-(4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin-4-yl}-1-méthyl-urée et de ses sels

Publications (1)

Publication Number Publication Date
MA33849B1 true MA33849B1 (fr) 2012-12-03

Family

ID=43983750

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35005A MA33849B1 (fr) 2009-12-07 2012-06-26 Formes cristallines de la 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1- {6-[4-(4-éthyl-pipérazin-1-yl) -phénylamino] -pyrimidin-4-yl} -1-méthyl-urée et de ses sels

Country Status (32)

Country Link
US (1) US9067896B2 (fr)
EP (1) EP2509963B1 (fr)
JP (2) JP5714024B2 (fr)
KR (1) KR101787784B1 (fr)
CN (5) CN111100078A (fr)
AR (2) AR079257A1 (fr)
AU (1) AU2010328391B2 (fr)
BR (1) BR112012013784B1 (fr)
CA (1) CA2781431C (fr)
CL (1) CL2012001480A1 (fr)
DK (1) DK2509963T3 (fr)
EC (1) ECSP12012026A (fr)
ES (1) ES2562462T3 (fr)
GT (1) GT201200181A (fr)
HR (1) HRP20160126T1 (fr)
HU (1) HUE026983T2 (fr)
IL (1) IL220012B (fr)
JO (1) JO3061B1 (fr)
MA (1) MA33849B1 (fr)
MX (1) MX2012006562A (fr)
MY (1) MY158333A (fr)
NZ (3) NZ700778A (fr)
PE (1) PE20121499A1 (fr)
PH (2) PH12014502593A1 (fr)
PL (1) PL2509963T3 (fr)
RU (1) RU2572848C2 (fr)
SG (1) SG10201408063SA (fr)
SI (1) SI2509963T1 (fr)
TN (1) TN2012000263A1 (fr)
TW (1) TWI526440B (fr)
WO (1) WO2011071821A1 (fr)
ZA (1) ZA201203612B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
EP2830626B1 (fr) * 2012-03-30 2019-01-02 Novartis AG Inhibiteur de fgfr destiné au traitement de troubles hypophosphatémiques
CA2876689C (fr) 2012-06-13 2022-04-26 Incyte Corporation Composes tricycliques substitues utilises comme inhibiteurs de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
WO2014155268A2 (fr) 2013-03-25 2014-10-02 Novartis Ag Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
SG11201602069WA (en) * 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
MY194303A (en) * 2013-12-13 2022-11-27 Novartis Ag Pharmaceutical dosage forms
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
WO2016027781A1 (fr) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 Sel de dérivé de pyridine monocyclique et son cristal
WO2016055916A1 (fr) 2014-10-06 2016-04-14 Novartis Ag Combinaison thérapeutique pour le traitement du cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (fr) 2015-02-20 2024-02-27 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016151501A1 (fr) 2015-03-25 2016-09-29 Novartis Ag Combinaisons pharmaceutiques
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
CN107660200B (zh) 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
WO2016189472A1 (fr) 2015-05-28 2016-12-01 Novartis Ag Inhibiteur de fgfr destiné à être utilisé dans le traitement de la tumeur mésenchymateuse phosphaturique
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
JP7372740B2 (ja) 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
TWI669300B (zh) * 2016-05-20 2019-08-21 浙江海正藥業股份有限公司 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
BR112019003722A2 (pt) * 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
AU2018361264B2 (en) 2017-11-01 2021-04-01 Guangdong Xianqiang Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN119751422A (zh) * 2019-10-14 2025-04-04 和记黄埔医药（上海）有限公司 化合物的盐及其晶型
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3202267A1 (fr) * 2020-12-18 2022-06-23 Riccardo Panicucci Methodes de traitement de l'achondroplasie
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
US11583602B2 (en) 2021-06-23 2023-02-21 Kimtron, Inc. System and method for ultra-close proximity irradiation of rotating biomass
WO2023174400A1 (fr) * 2022-03-18 2023-09-21 上海润石医药科技有限公司 Sel de composé hétérocyclique nitrique à six chaînons amino substitué, forme cristalline de celui-ci, procédé de préparation correspondant et utilisation associée
CN115785001B (zh) * 2022-11-23 2023-09-15 斯坦德药典标准物质研发(湖北)有限公司 一种英菲格拉替尼的制备方法
WO2024186882A1 (fr) 2023-03-06 2024-09-12 Qed Therapeutics, Inc. Méthodes de traitement de dysplasies squelettiques
AU2024345848A1 (en) * 2023-09-18 2026-04-09 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pharmaceutical composition containing heteroaryl oxynaphthalene compound, preparation method therefor, and use thereof
WO2025090870A1 (fr) 2023-10-27 2025-05-01 Qed Therapeutics, Inc. Infigratinib et ses métabolites destinés à être utilisés dans des méthodes de traitement d'affections du squelette

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101242843A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 作为激酶调节剂的氨基嘧啶类化合物
US20070129353A1 (en) * 2005-11-08 2007-06-07 Michael Kahn Alpha-helix mimetics and method relating to the treatment of cancer stem cells
ME00011A (fr) * 2005-12-21 2009-02-10 Novartis Ag Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf)
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas

Also Published As

Publication number Publication date
IL220012A0 (en) 2012-07-31
CA2781431A1 (fr) 2011-06-16
MY158333A (en) 2016-09-30
ECSP12012026A (es) 2012-08-31
PE20121499A1 (es) 2012-11-15
JP2015107996A (ja) 2015-06-11
BR112012013784B1 (pt) 2021-11-03
CL2012001480A1 (es) 2014-09-05
NZ700778A (en) 2015-04-24
PH12012501146A1 (en) 2012-10-22
SG10201408063SA (en) 2015-01-29
EP2509963A1 (fr) 2012-10-17
AU2010328391A1 (en) 2012-06-07
TW201144297A (en) 2011-12-16
US9067896B2 (en) 2015-06-30
TN2012000263A1 (en) 2013-12-12
CA2781431C (fr) 2017-10-31
HK1171016A1 (zh) 2013-03-15
PL2509963T3 (pl) 2016-05-31
HUE026983T2 (en) 2016-08-29
CN111100078A (zh) 2020-05-05
US20120245182A1 (en) 2012-09-27
NZ600070A (en) 2014-06-27
PH12014502593A1 (en) 2015-09-21
ES2562462T3 (es) 2016-03-04
CN111269186A (zh) 2020-06-12
JP5714024B2 (ja) 2015-05-07
CN102639510A (zh) 2012-08-15
HRP20160126T1 (hr) 2016-03-25
AR114946A2 (es) 2020-11-11
KR101787784B1 (ko) 2017-10-18
DK2509963T3 (en) 2016-02-29
MX2012006562A (es) 2012-07-04
BR112012013784A8 (pt) 2017-12-26
AU2010328391B2 (en) 2014-07-03
RU2572848C2 (ru) 2016-01-20
IL220012B (en) 2018-02-28
KR20130028045A (ko) 2013-03-18
RU2012128351A (ru) 2014-01-20
WO2011071821A1 (fr) 2011-06-16
JP6019142B2 (ja) 2016-11-02
EP2509963B1 (fr) 2015-11-25
ZA201203612B (en) 2013-01-30
GT201200181A (es) 2013-12-03
NZ624315A (en) 2014-11-28
TWI526440B (zh) 2016-03-21
JP2013512956A (ja) 2013-04-18
JO3061B1 (ar) 2017-03-15
CN105061332A (zh) 2015-11-18
AR079257A1 (es) 2012-01-04
BR112012013784A2 (pt) 2016-05-03
SI2509963T1 (sl) 2016-05-31
CN111100077A (zh) 2020-05-05

Similar Documents

Publication Publication Date Title
IL220012A0 (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
PT2486048T (pt) Métodos de produção de glicoproteínas em culturas de células de mamíferos utilizando glicocorticoides
DE112009004421T8 (de) RFID-Abtastsystem ohne äußere Energieversorgung zur Abfrage des strukturellen Befindens
BRPI0911773A2 (pt) eletrodo frontal transparente para uso em dispositivo fotovoltaico e método de produção do mesmo
BRPI0907004A2 (pt) Eletrodo frontal para uso em dispositivo fotovoltaico e método de produção do mesmo
MX2010007784A (es) 2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran -4-il)-propionamida cristalina.
BR112012003103A2 (pt) tratamento de células de astrócitos tumorais com inibidor de receptores de endotelina
EP2409696A4 (fr) Agent de promotion de la consommation énergétique
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BR112013032926A2 (pt) método para economizar energia e dispositivo de estação
ECSP11011383A (es) Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh
EA201171141A1 (ru) Твердый ретигабин в некристаллической форме
BRPI0923653A2 (pt) Conversão de ácido hexurônico em ácido hexárico
DK2307397T3 (da) 6-substituerede phenoxychroman-carboxylsyrederivater
EP2314219A4 (fr) Procédé et dispositif de capture d'image plantaire et usinage double face de la semelle obtenue selon ce procédé
EA201270345A1 (ru) Модифицированный фрагмент агрина, способный восстанавливать мышечную силу, для применения в качестве лекарства
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas
EP2506842A4 (fr) Formulations, sels et polymorphes de la transnorsertraline, et leurs utilisations
EP2488164A4 (fr) Libération d'agents par des cellules
BRPI0807250A2 (pt) "processo de conversão de so² em sais de interesse comercial"
BRPI1009765A2 (pt) "coletor e processo para flutuação de componentes insolúveis de sais brutos de potássio"
FR2930532B1 (fr) Potelet receptacle de petits dechets, notamment des megots
CY1117185T1 (el) Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων
DK2496555T3 (da) 4r,5s-enantiomer af 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamid med nootropisk aktivitet
AR109745A2 (es) Derivado de 4-pirimidinsulfamida